unknown
Stage
2018
Founded
2
Investors
About
Artiva Biotherapeutics develops off-the-shelf natural killer (NK) cell-based immunotherapies for cancer, including engineered and CAR-NK products intended to provide scalable allogeneic cell therapy options.
Explore Artiva Biotherapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.